ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

IL-15(N72D)/IL-15Ralpha-sFc Fusion Protein Complex FL115

Also written as “FL115” and “FL115+PD-1”.

Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms, led by Suzhou Forlong Biotechnology.

Drug pageIL-15(N72D)/IL-15Ralpha-sFc Fusion Protein Complex FL115: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jul 21, 20255 company-led studies, 4 open or runningNext primary completion: Dec 5, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Forlong Biotechnology54 open or runningphase 2since Jul 21, 2025Nov 7, 2023Dec 5, 2026phase 2 · NCT07131202

Also a collaborator on its studies: Novotech (Australia) Pty.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 7, 2023First study: phase 1 study in Locally Advanced/Metastatic Solid TumorsFirst studyNCT06130722 · 18 enrolled · United States
  2. Jul 21, 20252 phase 2 studiesNCT07131202, NCT07122414
  3. Jul 21, 2025Phase 1 study in Locally Advanced/Metastatic Solid TumorsNCT07131189 · 30 enrolled · China
  4. Aug 20, 2026Phase 1 study in Advanced Solid TumoursNCT07785193 · 29 planned · Australia

Ahead

  1. Dec 5, 2026Primary completion: phase 2 study in Advanced Solid TumorsNCT07131202
  2. Sep 2027Primary completion: phase 1 study in Advanced Solid TumoursNCT07785193
  3. Oct 10, 2027Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT07122414

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07785193Advanced Solid Tumours · Australia1Not yet recruitingSep 202729
NCT07131202Advanced Solid Tumors · China2RecruitingDec 5, 2026130
NCT07131189Locally Advanced/Metastatic Solid Tumors · China1Active, not recruitingJun 1, 202630
NCT07122414Non-Muscle Invasive Bladder Neoplasms · China2RecruitingOct 10, 202780
NCT06130722Locally Advanced/Metastatic Solid Tumors · United States1CompletedFeb 15, 202518

How it is read

Names in the registry

  • “FL115”, 4 entries
  • “FL115+PD-1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.